|Bid||79.50 x 900|
|Ask||145.59 x 800|
|Day's Range||90.43 - 95.63|
|52 Week Range||61.58 - 178.71|
|Beta (5Y Monthly)||0.72|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Biotech stock Ascendis Pharma reversed early losses Thursday to close with a gain despite a first-quarter miss for Skytrofa.
Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
A favorable commodity pricing scenario is likely to have aided Vermilion Energy's (VET) earnings in Q1.